Ashington

Researchers are evaluating the safety and effectiveness of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to understand how finerenone affects morbidity and mortality in this patient group. Participants will receive either oral finerenone or a matching oral placebo. The study focuses on patients currently hospitalized or recently discharged with heart failure symptoms and specific heart function measures. The trial is event-driven and will continue for up to approximately 30 months to collect sufficient data on outcomes. During the study, researchers will monitor the total number of heart failure events and cardiovascular deaths, as well as track serious adverse events and any adverse events that lead participants to stop the study drug. These ongoing assessments will help evaluate the overall safety and impact of the treatment over the duration of the trial.

Researchers are evaluating the effects of maridebart cafraglutide, given alongside standard care, in reducing heart failure events such as hospitalizations, urgent visits, cardiovascular deaths, and improving symptoms in people with heart failure who have preserved or mildly reduced ejection fraction and are obese. This is a global phase 3, multicenter trial with a two-part design including a double-blind period followed by an open-label extension. The first part will end once around 850 key events have been recorded. Participants will receive either maridebart cafraglutide or a placebo, both administered by injection under the skin. The study includes an initial randomized, double-blind phase and a later open-label extension where all participants may receive the active treatment. The trial is designed to monitor participants over time to assess the safety and effects of the treatment compared to placebo. During the trial, participants will undergo assessments including monitoring for cardiovascular events, heart failure symptoms, and laboratory tests such as NT-proBNP levels. Researchers will track time until the first occurrence of cardiovascular death or heart failure events over approximately 35 months. Safety evaluations, adherence to treatment, and ongoing health status will be followed throughout the study period.

The ARC Study is a national observational cohort study focused on patients undergoing primary hip and knee replacements, specifically for hip arthritis and knee arthritis. It aims to evaluate patient-reported and clinical outcomes following these surgeries, identify risk factors for adverse results, and find potential targets for future research and interventions. Additionally, the study serves as a resource to identify participants for future clinical trials and to provide comparison data for those trials. Participants undergo elective primary hip or knee replacement procedures and receive postoperative rehabilitation according to standard hospital care and their surgeon's preferences. The study collects data via an online portal where patients provide baseline demographics, lifestyle, health status, and patient-reported outcome measures before surgery. Follow-up data, including patient-reported outcomes, are collected through online questionnaires for up to two years after surgery. Participants join the study by consenting online, with recruitment occurring through outpatient clinics and advertising campaigns. Researchers collect and monitor health-related quality of life scores using the EQ-5D-5L questionnaire at two years post-surgery. The study also plans to embed multiple clinical trials within the cohort using a Trials within Cohorts (TwiCs) approach, enabling ongoing long-term data collection and participant involvement.

Researchers are evaluating the fluid absorption performance of two commonly used CE-marked superabsorbent dressings, Cutimed Sorbion and Zetuvit plus (RespoSorb), when applied to venous leg ulcers (VLUs) in routine wound care. The study aims to determine differences in how these dressings manage wound exudate and their ability to prevent skin maceration and leakage, which are important factors in promoting wound healing. Participants will receive one of the two superabsorbent dressings applied directly to their venous leg ulcer. The dressings are intended to maintain wound exudate effectively. This is a prospective, multicenter, partially assessor-blinded, randomized, open-label, parallel, comparative clinical trial comparing the exudate management performance of these products. During the study, participants will be monitored for up to 30 days to assess the dressings' ability to manage exudate. Researchers will evaluate the dressings' absorption performance, as well as any effects on skin maceration and leakage. Participants are expected to comply with study visits and standard therapies such as compression treatment while their wounds and overall health are regularly assessed throughout the study period.

Researchers are investigating heart failure patients with Non-Ischemic Cardiomyopathy (NICM), a condition where heart failure is not caused by blocked arteries. The study aims to compare survival rates between those who receive an Implantable Cardioverter-Defibrillator (ICD) and those who do not over a period of 36 months, with follow-up extending up to 10 years. This research could influence future international guidelines for managing this type of heart failure. Participants will be randomly assigned to one of two groups: one group will receive an ICD or a Cardiac Resynchronisation Therapy Defibrillator (CRTD), devices implanted under the skin that monitor and correct dangerous heart rhythms. The other group will not receive these devices. The device implantation is done under local anesthesia and includes leads fixed inside the heart chambers. Both groups will be monitored to see if the ICD reduces the risk of death. During the study, participants will undergo assessments including cardiovascular magnetic resonance imaging to evaluate heart scarring. Researchers will monitor survival rates and complications related to device implantation, such as bleeding, infections, or inappropriate shocks. The main outcome measured is the percentage of patients alive at 3 years. Safety and long-term effects will be followed to understand the balance of benefits and risks over time.

Aortic stenosis (AS) affects a significant portion of the elderly population, with approximately 5% of those over 65 years old and around 3% of those over 75 years having moderate to severe AS. The number of people with AS is increasing rapidly due to an aging population, creating challenges for clinicians in managing mostly elderly patients who are often symptom-free but have severe AS diagnosed incidentally. While symptomatic severe AS requires aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI), the best approach for asymptomatic patients remains unclear. This trial aims to compare early AVR or TAVI with standard expectant management in these patients to provide evidence on clinical outcomes and cost-effectiveness. The study is a large, multi-center randomized controlled trial conducted in the UK, Australia, and New Zealand, with plans to expand internationally. It includes two phases: a vanguard phase and a main phase, with an internal pilot to ensure adequate recruitment over two years. Eligible participants with severe asymptomatic AS will be randomly assigned to either early AVR or ongoing surveillance (expectant management). Those in the early AVR group will undergo surgery within about three months, which may include additional procedures like coronary angiography and possible coronary interventions if needed. The trial uses intention-to-treat analysis to compare outcomes between groups. Participants will be closely monitored throughout the study, with evaluations including routine tests and assessments as part of their care. The primary outcome measured is a combination of cardiovascular death and hospitalization for heart failure over a minimum of three years. The study also collaborates with another trial, EVoLVeD, offering participants additional research opportunities. Overall, the study seeks to provide important data on whether early valve replacement before symptoms develop can improve outcomes for people with severe asymptomatic AS.